Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 13/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 13/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.39 |
| ▸ | HTR1D | P28221 | 1/20 | 0.33 |
| ▸ | HTR1B | P28222 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7858368 | 0.80 | CHRNB2 (0.60) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL2914386 | 0.76 | CHRNB2 (0.40) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL6545918 | 0.75 | CHRNB2 (0.56) | CHRNB2CHRNA4 | |
| SCHEMBL2916099 | 0.74 | CHRNB2 (0.63) | CHRNB2CHRNA4CHRNB4CHRNA3HTR1D | |
| SCHEMBL20963039 | 0.74 | PSEN1 (0.38) | NPC1ALDH1A1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL20963063 | 0.74 | PSEN1 (0.38) | NPC1ALDH1A1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL11699947 | 0.72 | CHRNB2 (0.56) | CHRNB2CHRNA4 | |
| SCHEMBL11703659 | 0.70 | CHRNB2 (0.54) | CHRNB2CHRNA4 | |
| SCHEMBL11703811 | 0.70 | CHRNB2 (0.54) | CHRNB2CHRNA4 | |
| SCHEMBL7291366 | 0.70 | CHRNB2 (0.35) | CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110003802-A1 | Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-7345056-B2 | Bridged N-cyclic sulfonamido inhibitors of gamma secretase | ELAN PHARMACEUTICALS, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-20070049612-A1 | Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003802-A1 | Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase | BACE1, BACE2, PSEN1 | CHRNB2 124/4885CHRNA4 261/4885CHRNB4 262/4885 |
| US-20070049612-A1 | Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase | BACE1, BACE2, PSEN1 | CHRNB2 124/4885CHRNA4 261/4885CHRNB4 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.